Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
OtherContinuing Education (Invitation Only)

SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer— Use of Imaging Agents in Therapeutic Drug Development and Approval

Charlotte D Jeffers, Courtney Lawhn-Heath, Regan I Butterfield, John M. Hoffman and Peter J. H. Scott
Journal of Nuclear Medicine Technology June 2022, jnmt.122.264372; DOI: https://doi.org/10.2967/jnmt.122.264372
Charlotte D Jeffers
1 University of Alabama at Birmingham, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Lawhn-Heath
2 University of California San Francisco;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regan I Butterfield
3 Huntsman Cancer Institute, University of Utah;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Hoffman
4 University of Utah School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. H. Scott
5 University of Michigan, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The process of bringing a new drug to market is complex and has recently necessitated a new drug discovery paradigm for the pharmaceutical industry that is both more efficient and more economical. Key to this has been the increasing use of nuclear medicine and molecular imaging to support drug discovery efforts by answering critical questions on the pathway for development and approval of a new therapeutic drug. Some of these questions include: (i) Does the new drug reach its intended target in the body at sufficient levels to effectively treat or diagnose disease without unacceptable toxicity? (ii) How is the drug absorbed, metabolized, and excreted? (iii) What is the effective dose in humans? To conduct the appropriate imaging studies to answer such questions, pharmaceutical companies are increasingly partnering with molecular imaging departments. Nuclear medicine technologists are critical to this process as they perform scans to collect the qualitative and quantitative imaging data used to measure study endpoints. This article describes preclinical and clinical research trials and provides an overview of the different ways that radiopharmaceuticals are used to answer critical questions during therapeutic drug development.

  • PET
  • Radiopharmaceuticals
  • Other
  • PET and SPECT
  • clinical research
  • clinical trials
  • drug development
  • nuclear medicine

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 50 (2)
Journal of Nuclear Medicine Technology
Vol. 50, Issue 2
June 1, 2022
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer— Use of Imaging Agents in Therapeutic Drug Development and Approval
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer— Use of Imaging Agents in Therapeutic Drug Development and Approval
Charlotte D Jeffers, Courtney Lawhn-Heath, Regan I Butterfield, John M. Hoffman, Peter J. H. Scott
Journal of Nuclear Medicine Technology Jun 2022, jnmt.122.264372; DOI: 10.2967/jnmt.122.264372

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer— Use of Imaging Agents in Therapeutic Drug Development and Approval
Charlotte D Jeffers, Courtney Lawhn-Heath, Regan I Butterfield, John M. Hoffman, Peter J. H. Scott
Journal of Nuclear Medicine Technology Jun 2022, jnmt.122.264372; DOI: 10.2967/jnmt.122.264372
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
  • Diuretic Renal Scintigraphy Protocol Considerations
Show more Continuing Education (Invitation Only)

Similar Articles

Keywords

  • PET
  • Radiopharmaceuticals
  • Other
  • PET and SPECT
  • clinical research
  • clinical trials
  • drug development
  • nuclear medicine
SNMMI

© 2022 Journal of Nuclear Medicine Technology

Powered by HighWire